HeartFlow, Inc. is a publicly traded company on Nasdaq (HTFL) that applies artificial intelligence and computational modeling to cardiovascular diagnostics. Its technology focuses on coronary artery disease (CAD), using patient-specific 3D simulations to assess the functional significance of coronary narrowings from standard cardiac CT scans. The company's platform is designed to support clinical decision-making along the guideline-directed CCTA pathway.
The company's product suite includes HeartFlow One, a non-invasive precision coronary care platform, alongside specific analyses for plaque characterization, coronary narrowing visualization, and blood flow simulation (FFRCT). These tools are used by more than 1,800 institutions globally. The company's analyses have been applied to over 600,000 patients and are supported by more than 625 peer-reviewed publications.
HeartFlow's coverage in the United States extends to 99.5% of lives through Medicare and major commercial insurers. The company maintains a presence in San Francisco, California, as well as in Europe and Japan. Its core technical domains include AI, 3D modeling, medical imaging analysis, and computational fluid dynamics.
